Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
NCT05403450 · Taiho Oncology, Inc. · PHASE1 · terminated · last registry update 2026-10-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “ASTX660-03 was closed according to protocol as no safe and tolerable dosing for the combination of tolinapant and decitabine/cedazuridine was identified based on protocol defined criteria.” | – | Registry record, Taiho Oncology, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CDA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-06Results posted on the registry: National Cancer Institute (NCI), Cytarabine + Daunorubicin (NCT04817241)
- 2026-08-24Also stopped (suspended): National Cancer Institute (NCI), Decitabine and Cedazuridine + Venetoclax (NCT06802523)
- 2026-07-31Also stopped (suspended): National Cancer Institute (NCI), Decitabine and Cedazuridine + Paclitaxel (NCT05673200)
- 2026-05-15Also stopped (withdrawn): M.D. Anderson Cancer Center, ASTX727 + Donor Lymphocyte Infusion (NCT06297629)
- 2026-02-13Also stopped (withdrawn): M.D. Anderson Cancer Center, ASTX029 + ASTX727 (NCT06284460)
- 2026-01-09Results posted on the registry: Sanjay Mohan, Venetoclax + Decitabine (NCT05799079)
- 2026-01-09Also stopped (terminated): Sanjay Mohan, Venetoclax + Decitabine (NCT05799079)
- 2025-12-02Results posted on the registry: National Cancer Institute (NCI), KPT-8602 + Inqovi (NCT05918055)
- 2025-12-02Also stopped (terminated): National Cancer Institute (NCI), KPT-8602 + Inqovi (NCT05918055)
- 2025-11-12Also stopped (terminated): Roswell Park Cancer Institute, Decitabine and Cedazuridine + Enzalutamide (NCT05037500)
- 2025-10-16Also stopped (terminated): Novartis Pharmaceuticals, MBG453 + Azacitidine (NCT04878432)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision